Uvedená je stručná kazuistika prvého pacienta liečeného natalizumabom v Slovenskej republike pri diagnóze sclerosis multiplex. Natalizumab je prvou monoklonálnou protilátkou schválenou pre liečbu tohoto ochorenia. Liečba natalizumabom u tohoto pacienta bola indikovaná pre výraznú progresiu ochorenia napriek pokračujúcej liečbe interferonom beta. Stav pacienta doposiaľ po absolvovaní 11 mesačnej liečby natalizumabom je stabilizovaný. Pri kontrolnom MR vyšetrení po polroku liečby natalizumabom je zreteľná redukcia veľkosti zápalových ložísk. Liek je nádejou pre pacientov s agresívnymi prejavmi ochorenia ako aj pri zlyhaní inej imunomodulačnej liečby.

A case report of the first patient with MS treated with natalizumab in the Slovak Republic is presented. Natalizumab is the first monoclonal antibody approved for treatment of MS. Therapy was indicated for significant progression of the disease despite therapy with interferon beta. Patient´s status is stabile after 11 months therapy with natalizumab. Control MR examination after 6 months therapy with natalizumab revealed apparent reduction in size of inflammatory foci. The drug seems to be the hope for patients with aggressive symptoms of the illness as well as for failure of other immunomodulate therapy.

First experiences with treatment of multiple sclerosis with natalizumab (tysabri)